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MKP-1 DUSP1are mediated via the GC-receptor (GR), which either stimulates or represses gene
expression. Repression of target genes often involves negative cross-talk between the GR and other
transcription factors e.g. NF-κB, important for gene activation. Using HEK293 cells we here describe that
repression of NF-κB requires functions of the GR that are dependent on the signaling pathways employed to
activate NF-κB. While a GR mutant was able to repress NF-κB activity following activation by TNFα, it did not
so following activation by the phorbol ester TPA. In these cells, TPA stimulation but not TNFα, activated
extracellular signal-regulated kinase (ERK). We demonstrated that the ability of the dexamethasone
activated GR mutant to repress TPA-induced NF-κB activity was restored in conjunction with ERK1/2
inhibition. Previous reports have shown GC-mediated inhibition of ERK1/2 phosphorylation to involve GC
induction of MAPK phosphatase-1 (MKP-1). Here, we demonstrated that the GRR488Q mutant was incapable
of inducing gene expression of endogenous MKP-1 following dexamethasone treatment, in contrast to the
GRwt. However, TPA treatment alone resulted in much stronger MKP-1 expression in both GRwt and GRR488Q
containing cells than that of dexamethasone suggesting that the inability of GRR488Q to inhibit TPA-induced
NF-κB activity did not involve a lack of MKP-1 expression. In line with this, RNAi targeted towards MKP-1 did
not abolish or inhibit the ability of the GRwt to repress NF-κB activity. Importantly, we observed no difference
in activated ERK1/2 (phospho-ERK1/2) expression over time between GRwt and GRR488Q containing cells
following co-treatment with TPA and dexamethasone. Based on these results we suggest that GRwt does not
directly regulate ERK1/2 but rather alters ERK1/2-mediated effects allowing it to repress NF-κB activity, a
capacity lacked by the GRR488Q mutant.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe cell is constantly exposed to a number of signals that
simultaneously trigger several separate signal transduction pathways.
Activation of cellular signaling cascades ultimately leads to changes in
the activity of nuclear transcriptional regulators that modulate gene
transcription. In order for the cell to handle multiple transduction
pathways activated simultaneously, sometimes signaling opposite
effects, the cell utilizes highly controlled ways to integrate the
different transduction cascades. This communication between diffe-
rent signaling pathways is referred to as “cross-talk”. This usually
involves a physical interaction between proteins belonging to the
individual signal transduction pathways or enzymatic modiﬁcation
e.g. phosphorylation/dephosphorylation that ultimately will change
the activity of the effector proteins. This cross-talk does not onlyes and Nutrition, Karolinska
ovum, SE-141 86 Huddinge,
l rights reserved.integrate multiple signals but also contributes to the generation of
cell-speciﬁc responses, dependent on which signal transduction
pathways are activated at a given time and the “menu” of available
active factors present in the responsive cell.
One physiologically important example of cross-talk between
separate signaling pathways is the repression of NF-κB activity by
glucocorticoids (GCs). This cross-talk constitutes a key component for
the anti-inﬂammatory effect exerted by GCs and may also be of
importance in the anti-proliferative activity of GCs [1–4]. NF-κB is a
transcription factor and a key regulator of a variety of genes involved
in e.g. inﬂammatory processes, growth control and apoptosis [5]. In its
inactive form, NF-κB resides in the cytoplasm through its interaction
with the inhibitory protein, IκB, which masks the nuclear localization
signal of the NF-κB complex. A variety of stimuli trigger activation of
NF-κB, including proinﬂammatory cytokines e.g. tumor necrosis factor
α (TNFα), phorbol esters and lipopolysaccharides. Activation by these
agents leads to phosphorylation of IκB, targeting it to ubiquitin
dependent degradation by the 26S proteasome, thus, allowing the NF-
κB complex to translocate to the nucleus, interact with NF-κB binding
sites in target genes and to stimulate gene transcription [6].
Dependent on the signal used to stimulate NF-κB and the cell type
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simultaneously be activated in the cell e.g. the mitogen-activated
protein kinase (MAPK) signaling cascade. These additional pathways
may directly inﬂuence NF-κB activity or they may regulate a third
pathway that in turn inﬂuences NF-κB activity [7,8].
GCs exert their effects following binding to the GC-receptor (GR).
TheGR functions as a ligand (GC) dependent transcription factor. In the
absence of ligand, the receptor resides in the cytoplasm and upon
ligandbinding theGRhomodimerizes, becomeshyper-phosphorylated
and translocates to the nucleus [4,9]. The GC activated GR acts at the
level of gene transcription, where it either activates or represses
expression of target genes. Transcriptional activation usually occurs
when GR binds to so called GC-responsive elements (GREs) in
promoter regions of target genes. Repression of transcription by the
GR is often GRE-independent and takes place via a physical interaction
between the GR and other transcription factors or co-activators
without the GR directly contacting the DNA. One such transcription
factor targeted by the GR is the NF-κB. In this case, the GR is thought to
inactivate NF-κB without displacing NF-κB from the DNA [10,11]. This
protein-protein interaction between GR and NF-κB on the DNA
(tethering) is a key step in the cross-talk mechanism by which GCs
repress NF-κB activity [2,4]. Furthermore, it has been shown that this
interaction leads to the displacement or blockage of recruitment by
NF-κB of co-activators important in transcriptional activation by NF-κB
[12–15]. GR mediated interference with NF-κB activity has also been
suggested in some cells to involve up-regulation of the inhibitory
protein, IκBα thatmay lead to retention of NF-κB in the cytoplasm (see
[1,2,4] for refs). It has also been demonstrated that GCs can inhibit the
activity of the mitogen-activated protein kinase (MAPK) signaling
cascades, including the extracellular signal-regulated kinase 1 and 2
(ERK1/2) pathway [16–21]. ERK1/2 is activated by a series of up-stream
phosphorylation events following stimulationwith e.g. growth factors
and phorbol esters [22]. ERK1/2 activation involves dual phosphoryla-
tion at conserved tyrosine and threonine residues by the immediate
up-stream kinases, MEK1/2. Negative regulation of ERK1/2 takes place,
at least in part, through dephosphorylation of ERK1/2 by dual-
speciﬁcity phosphatases, e.g.MAPKphosphatase-1 (MKP-1) also called
dual speciﬁcity phosphatase 1 (DUSP1) [23–26]. We and others have
shown that GCs can induce MKP-1 expression in a wide variety of cell
types [18,19,27–33], which could explain GC inactivation of the ERK
signaling pathway. However, reports demonstrating the effects of
MKP-1 inactivation for GR dependent responses are contradictory
[34,35]. More speciﬁcally, the role of GC-induced MKP-1 expression in
NF-κB repression by GCs is unclear.
We have previously demonstrated that a point mutation (R→Q) at
position 488 (rat nomenclature) in the GR DNA binding domain (DBD)
impairs the capacity of the receptor to repress TPA-induced NF-κB
activity [36]. Interestingly, GRR488Q failed to repress NF-κB activity
despite still being able to physically interact, similarly to the wild type
GR (GRwt), with NF-κB. However, during our further investigations of
the mechanism responsible for the failure of GRR488Q to repress NF-κB
activity, we observed that this was dependent on the signal used to
activate NF-κB. In contrast to the inability of GRR488Q to repress NF-κB
activity following TPA administration, GRR488Q was able to repress NF-
κB activity when activated by TNFα (presented in this report). Thus,
the inability of GRR488Q to repress NF-κB activity involved separate GR
functions dependent on the signaling transduction pathways acti-
vated in the cells. The aim of this studywas to evaluate the importance
of ERK MAPK signaling in GC-mediated repression of NF-κB activity
and a possible role of GC-induced up-regulation of MKP-1 expression
for this response. We here show that the ability of GR to efﬁciently
repress NF-κB in HEK293 cells requires inhibition of ERK1/2 signaling.
However, GR-mediated NF-κB repression does not depend on GC-
induced up-regulation of MKP-1 expression or GC inhibition of ERK
itself, but rather involves the alteration of effects mediated by
activated ERK.2. Materials and methods
2.1. Reagents and chemicals
Dexamethasone (Dex) and 12-O-tetradecanoyl-phorbol-13-acetate
(TPA) were purchased from Sigma (St Louis, MO, USA). TNFα and
U0126 were purchased from Boehringer Mannheim (Indianapolis, IN,
USA) and Cell Signaling Technology (Beverly, MA, USA), respectively.
The culture media DMEM (high glucose) and F12 (HAM), penicillin/
streptomycin, zeocin, hygromycin, L-glutamine, and Lipofectin® and
Lipofectamin® 2000 reagent were purchased from Invitrogen (Carls-
bad, CA, USA). FuGENE® 6 reagent was purchased from Roche
Diagnostics Corporation (Indianapolis, IN, USA). Fetal bovine serum
(FBS) was purchased from Saveen Werner AB (Malmö, Sweden) and
the chemiluminescence reagents used for measurement of alkaline
phosphatase and luciferase activity were purchased fromPerkin Elmer
Life Sciences (Boston, MA, USA) and BioThema (Handen, Sweden),
respectively. Primers were obtained from DNA Technology A/S
(Aarhus, Denmark) and all reagents used for real-time PCR were
purchased from Applied Biosystems (Foster City, CA, USA).
2.2. Reporter and expression plasmids
The luciferase reporter plasmid3x(NF-κB)tk-Luc [37], thedominant-
negative MEK1 expression plasmid S222A [38], the rat GR expression
and 2x(GRE)tk-Luc plasmids [39] have beendescribed previously. CMV-
ALP was used as internal control to normalize for differences in
transfection efﬁciency.
2.3. Cell culture
Maintenance of HEK293 Flp-In cells (Invitrogen, Carlsbad, CA, USA)
and generation of pooled clones of HEK293 Flp-In cells stably
transfected with wild type GR (GRwt) or the GR mutant GRR488Q
have previously been described [36]. All clones express similar
amounts of GR protein (∼80,000 receptors per cell).
2.4. Transfection
Lipofectin®, FuGENE® 6 or Lipofectamin® 2000 (for RNAi experi-
ments) was used in all transfection experiments according to the
manufacturer's instructions. The GR expression plasmids and the
reporter gene plasmidswere used at a concentration of 25 ng/well and
200 ng/well, respectively. The plasmid CMV-ALP was used as an
internal control at a concentration of 1 ng/well. Brieﬂy, 30,000 cells/
well were seeded in 24-well plates 24 h prior to transfection. Twenty
hours post transfection, cells were exposed to treatment, 100 nM
dexamethasone±5 ng/ml TPA or ± 200 U/ml TNFα in the presence or
absence of 10 μM U0126, for 20 h and the cell medium was collected
and cell extract was prepared for measuring alkaline phosphatase and
luciferase activities as described [36].
2.5. RNAi experiments and real-time PCR (RT-PCR)
RNAi for human MKP-1 (also called DUSP1) was obtained from
Invitrogen. The target sequence (sense strand) for theMKP-1 validated
StealthTM RNAi duplex 1 is 5′-GCCUUGAUCAACGUCUCAGCCAAUU-3′
and for duplex 2, 5′-CCACCAUCUGCCUUGCUUACCUUAU-3′. Control
RNAi with the same GC content was also obtained from Invitrogen
(Cat. No. 12935-300). 300,000 cells/well of HEK293 cells stably
expressing the GRwt were plated in six-well plates and transfected
the next day using Lipofectamin® 2000 (Invitrogen) according to the
protocol provided by the manufacturer. Cells were transfected with
400pmol of RNAi in a volume 0.5 ml for 24 h after which the cells were
exposed to an additional 0.5 ml of complete medium containing
vehicle, 100 nM Dex, 5 ng/ml TPA (ﬁnal concentrations) or a
Fig. 1. GRR488Q has the ability to repress NF-κB activity stimulated by TNFα but not TPA.
(A) Both GRwt and GRR488Q repress TNFα-stimulated NF-κB activity. Pooled clones of
HEK293 cells stably expressing GRwt and GRR488Q, respectively, were transiently
transfected with an NF-κB-regulated reporter gene (3x(NF-κB)tk-Luc) and the internal
control vector CMV-ALP. 20 h post transfection cells were exposed to vehicle (open bars),
200 U/ml TNFα (vertical striped bars) or 200 U/ml TNFα + 100 nM Dex (horizontal
striped bars) for 20 h. (B) GRwt, in contrast to GRR488Q mutant, represses TPA-stimulated
NF-κB activity. Same protocol as in “A”with the exception that 5 ng/ml TPA (black bars)
or 5 ng/ml TPA+100 nM Dex (gray bars) were used. The luciferase activity was
normalized to the activity of the internal control (alkaline phosphatase). The luciferase
activity following TNFα and TPA stimulation, respectively, was given the nominal value
of 100 in each experiment and the results for the other conditions were expressed
relative to this nominal value. RLU, relative light units. Data represent mean±SD. ns, not
signiﬁcant. Each experiment was performed in triplicate and repeated three times.
Fig. 2. TPA but not TNFα induces phosphorylation of ERK1/2 in HEK293 cells. Western
blot analysis of phosphorylated ERK1/2 in HEK293 cells following 15 min exposure to
vehicle (Ctrl), 5 ng/ml TPA or 200 U/ml TNFα. ERK1/2 phosphorylation was assessed
using a phospho-speciﬁc ERK antibody.
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RNAi. Cells were harvested, total RNA isolated and mRNA expression
was analyzed by RT-PCR as described [36]. Forward primer for MKP-1
is 5′-CGAGGCCATTGACTTCATAGACT-3′ and the reverse primer is 5′-
CAAACACCCTTCCTCCAGCAT-3′. Primers for analysis of Cox-2, JunB and
GAPDH mRNA, the latter used to normalize all qRT-PCR results, have
been given before [36]. In the case of the studies of the effect of MKP-1
RNAi on NF-κB-Luc activity, 3x(NF-κB)tk-Luc and CMV-ALP reporter
plasmids were ﬁrst transfected with FuGENE® 6 reagent for 6 h
according to themanufacturer's description. After allowing the cells to
recover for 18 h, cells were then retransfected with RNAi using
Lipofectamin® 2000 as described above.
2.6. Western blot analysis
Whole cell extract was prepared from cells cultured to subcon-
ﬂuence by lysing the cells in ice-cold Nonidet P-40 (NP-40) buffer
(0.5% NP-40, 50 mM Tris–HCl pH 8.0, 150 mM NaCl, 5 mM EDTA) for
20 min. Cell debris was removed by centrifugation at 14,000 ×g for
15 min at 4 °C and an equal volume of 2×SDS loading buffer was
added to the supernatant and the mixture was boiled for 2 min.
Protein concentrations were determined with the BioRad protein
assay kit according to the instructions from the manufacturer
(BioRad, Hercules, CA, USA). Samples were separated by 9% SDS-
polyacrylamide gel electrophoresis and electroblotted onto a Hybond
C-extra membrane (Amersham Biosciences, UK). The immunoblot
was probed with an antibody against MKP-1 (sc-1104, Santa CruzBiotechnology, CA, USA). ERK1/2 or a phospho-speciﬁc ERK1/2
antibody (Cell Signaling Technology, MA, USA) or β-actin (Abcam,
Cambridge, UK) followed by a secondary horseradish peroxidase-
labeled anti-rabbit antibody (Amersham Biosciences, UK). The
immunoreactivity of ERK, MKP-1 and β-actin was visualized using
the enhanced chemiluminescence kit (Amersham Biosciences, UK)
according to the manufacturer's instructions.
2.7. Statistics
Data were analyzed using a two-tailed Student's t-test. The results
were expressed as means±SD.
3. Results
3.1. TNFα- but not TPA-induced NF-κB activity is repressed by GRR488Q
The previously described GR mutant, GRR488Q, despite physically
interacting with NF-κB, lacks the ability to repress NF-κB activity
following activation by phorbol ester (TPA) [36]. This suggests that
physical interaction between GR and NF-κB is not sufﬁcient to impair
NF-κB activity. To search for other mechanisms that are important for
GC-mediated repression of NF-κB activity, we tested if the impaired
ability of GRR488Q to repress NF-κB activity was dependent on the
stimuli used to activate NF-κB. For this purpose we activated NF-κB
using TNFα, another potent NF-κB activator, in HEK293 cells. Transient
transfection of the reporter gene 3x(NF-κB)tk-Luc was used to
measure NF-κB activity in pooled HEK293 clones stably expressing
GRwt and GRR488Q, respectively. The results showed that, similar to
GRwt, dexamethasone activated GRR488Q was able to repress TNFα-
induced NF-κB activity (Fig. 1A). This was in contrast to TPA-induced
NF-κB activity, which only was repressed by GRwt and not by GRR488Q
(Fig. 1B). This demonstrated that this mutation impaired the NF-κB
repressive property of the GR during deﬁned, but not all, conditions.
This also showed that the inability of GRR488Q to repress NF-κB activity
was not due to bona ﬁde alterations in the receptor protein.
Accordingly, this provided evidence for that GR-mediated repression
of activated NF-κB required separate functions of the GR, functions
that were dependent on the signaling pathway employed to activate
NF-κB.
3.2. TPA, but not TNFα , activates ERK1/2 in HEK293 cells and
TPA-induced NF-κB activity is repressed by GRR488Q in conjunction
with ERK1/2 inhibition
The reason for the different ability of GRR488Q to repress NF-κB
activity following TPA and TNFα stimulation respectively, may
correlate to different signaling pathways being activated following
treatment with respective stimuli. We observed that the mitogen-
activated protein kinase (MAPK) pathway was differentially activated
following TPA versus TNFα stimulation in HEK293 cells. Immunoblot-
ting following TPA and TNFα treatment showed that TPA treatment
but not TNFα treatment resulted in ERK1/2 activation (Fig. 2). This
differential proﬁle of ERK1/2 activation in response to a given stimuli
could explain why GRR488Q was able to repress NF-κB activity
following TNFα stimulation but not after TPA stimulation.
Fig. 3.MEK-1 inhibition by the dominant-negative MEK-1 S222A mutant or the MEK-1
inhibitor U0126 restores the ability of GRR488Q to repress TPA-induced NF-κB activity.
(A) HEK293 cells stably expressing GRR488Q were transiently co-transfected with an
NF-κB-regulated reporter gene (3x(NF-κB)tk-Luc), the internal control vector CMV-ALP
and the dominant-negative MEK-1 expression plasmid MEK-1 S222A or empty
expression vector as control. In (B) the MEK-1 inhibitor U0126 was used instead of
the MEK-1 S222A expression plasmid. 20 h post transfection cells were exposed to
vehicle (open bars), 5 ng/ml TPA (black bars) or 5 ng/ml TPA + 100 nM Dex (gray bars)
and 10 μM U0126 when indicated for 20 h. U0126 was added 1 h prior to the other
treatments. RLU from TPA treatment alone in the absence of MEK-1 S222A or U0126was
given the nominal value of 100 and the results for the other conditions were expressed
relative to this nominal value. (C) HEK293 cells stably expressing GRR488Q were
transiently co-transfected with the 2x(GRE)tk-Luc reporter gene and the internal
control vector CMV-ALP and treated with dexamethasone (100 nM), TPA (5 ng/ml) or a
combination thereof in the presence or absence of 10 μM U0126 for 20 h. U0126 was
added 1 h prior to the other treatments. RLU from untreated samples were given the
nominal value of 1 and the results for the other conditions were expressed relative to
this nominal value. Data represent mean±SD. The experiments were performed in
triplicate and repeated three times. ns, not signiﬁcant.
Fig. 4. MEK-1 inhibition by the speciﬁc metabolic inhibitor U0126 enhances the ability
of GRR488Q to repress TPA-induced Cox-2 and JunB expression. (A) Western blot analysis
of ERK phosphorylation following stimulation by TPA. HEK293 cells were treated with
5 ng/ml TPA (TPA) or 5 ng/ml TPA + 10 μM U0126 (TPA+U0126). U0126 was added 1 h
prior to the TPA treatment (15 min). ERK1/2 phosphorylation was assessed using a
phospho-speciﬁc ERK antibody. (B and C) HEK293 cells stably expressing GRR488Q were
treated with 5 ng/ml TPA (black bars) or 5 ng/ml TPA + 100 nM Dex (gray bars) for 2 h in
the presence or absence of 10 μM U0126. The U0126 was added 1 h prior to the other
treatments. Total RNA was extracted from the cells and Cox-2 (B) and JunB (C) mRNA
expression was determined by RT-PCR. Results were related to GAPDH mRNA
expression. TPA treatment alone was given the nominal value of 100 and the results
from the other conditions were expressed relative to this value. Data shows the mean of
two experiments.
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responses is required for GC-induced repression of NF-κB activity
would predict that inhibition of ERK1/2 will restore the ability ofGRR488Q mutant to inhibit NF-κB following TPA stimulation. To test
this prediction, we inhibited ERK activation by blocking the upstream
ERK-activating kinase MEK-1 using a dominant-negative MEK-1
mutant S222A [38]. HEK293 cells stably expressing GRR488Q were
transfected with an NF-κB-regulated reporter gene and an expression
vector for MEK-1 S222A followed by TPA treatment in the presence or
absence of dexamethasone. In line with the hypothesis, MEK-1
inhibition by the dominant-negative MEK-1 S222A restored the ability
of GRR488Q to repress TPA stimulated NF-κB activity in the presence of
dexamethasone (Fig. 3A). The same result was seenwhen ERK1/2 was
inhibited by the MEK-1 inhibitor U0126 (Fig. 3B). Co-transfection of
the dominant-negative MEK-1 mutant S222A resulted in a small but
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while U0126 treatment resulted in small but non-signiﬁcant increase
(Fig. 3B). Similarly, no signiﬁcant change in NF-κB activity after
stimulation by TNFα in the presence of the ERK inhibitor U0126 was
observed (data not shown). These results clearly showed that GC-
mediated NF-κB repression was dependent on the absence of
activated ERK1/2 or ERK1/2-mediated effects following stimulation
by TPA and that ERK1/2 inhibition had no or only aminor effect on TPA
or TNFα stimulated NF-κB activity in the absence of dexamethasone.
Previous reports have suggested that ERK1/2 may directly inhibit
GR activity [40–42]. Thus, the ability of GRR488Q to repress NF-κB
activity following ERK1/2 inhibition may be due to a relief of the
inhibitory effect by the ERK1/2 inhibitors. To test this, HEK293 cells
stably transfected with GRR488Q were transiently transfected with the
2x(GRE)tk-Luc reporter gene in the absence or presence of the ERK1/2
inhibitor U0126. As can be seen in Fig. 3D, dexamethasone induced
GRR488Q to activate the 2x(GRE)tk-Luc reporter gene 11-fold in the
presence or absence of U0126. As previously demonstrated, this was
markedly less as compared to the GRwt, which induced GRE-Luc
activity 80-fold ([36] and data not shown). TPA alone induced
the reporter gene 8- and 11-fold in HEK293 GRR488Q cells in the
absence and presence of U0126, respectively. Co-treatment with
TPA+dexamethasone resulted in a slight synergistic activity (Fig. 3D).
More importantly, no difference in the response in the absence or
presence of U0126 was seen, demonstrating no enhanced GR activity
in the presence of ERK1/2 inhibition. This showed that TPA and ERK1/2
activation in itself did not block GR activity in the HEK293 cells.Fig. 5. Reducing MKP-1 expression by RNAi does not impair the ability of the GRwt to repre
expressing the GRwt were transfected with RNAi's oligos targeting MKP-1 mRNA or control
100 nM Dex (squared bars), 5 ng/ml TPA (black bars) or 5 ng/ml TPA + 100 nM Dex (gray bars
for MKP-1 (A) and Cox-2 (D) was analyzed by RT-PCR. All values are related to GAPDH mRNA
relative mRNA expression are all expressed in relation to the mRNA expression obtained in c
Panels A and D represent the results obtained from one out of two experiments with similar r
immunoblotting (C) HEK293 cells were transiently co-transfected with GRwt expression vect
CMV-ALP. After recovering for 18 h the cells were re-transfected with control or MKP-1 RNA
extracts were prepared and luciferase activity measured. The RLU from cells transfected with
for the other conditions were expressed relative to this nominal value. Data represent mean3.3. Inhibition of ERK1/2 activity enhances the ability of GRR488Q to
repress endogenous NF-κB-regulated genes following
dexamethasone administration
To test whether ERK1/2 inhibition also affects repression of
endogenous NF-κB-regulated genes, GRR488Q containing HEK293
cells were treated with the MEK-1 inhibitor U0126 in conjunction
with TPA activation. Previous results have shown that GRR488Q, in
contrast to the GRwt, is impaired with regard to its capacity to repress
the endogenous NF-κB-regulated genes Cox-2 and JunB following
activation by TPA [36]. HEK293 cells stably expressing the GRR488Q
mutant were treated with TPA and dexamethasone in the presence or
absence of U0126 followed by analysis of Cox-2 and JunB expression
by real-time PCR (RT-PCR). The ability of U0126 to inhibit ERK1/2
activation in HEK293 cells was conﬁrmed by Western blot analysis
(Fig. 4A). Fig. 4B demonstrates that inactivation of ERK in HEK293
GRR488Q cells by U0126 enhanced fold-repression by dexamethasone
of the endogenous NF-κB-regulated gene Cox-2. Similar results were
seen for JunB gene expression (Fig. 4C). The ability of the ERK1/2
inhibitor U0126 to enhance fold repression of Cox-2 and JunB
following GC treatment supported the conclusion that absence of
ERK1/2 signaling or effects also was important for efﬁcient GC
inhibition of endogenous NF-κB-regulated genes following TPA
stimulation in HEK293 cells. Furthermore, U0126 seemed to repress
TPA-stimulated Cox-2 and JunB expression by ∼30–40%, indicating a
role of ERK in TPA activation of Cox-2 and JunB expression. However,
since ERK inhibition had no or only a minor effect on NF-κB activityss TPA-stimulated NF-κB activity or endogenous Cox-2 expression. HEK293 cells stably
RNAi. Twenty-four hours post transfection, cells were exposed to vehicle (open bars),
) for 16 h (without removing the RNAi's). Total RNAwas extracted and mRNA expression
expression which was unaffected by the MKP-1 RNAi's or control RNAi treatment. The
ells transfected with control RNAi and no treatment and given the nominal value of 100.
esults. (B) Protein levels of MKP-1 following RNAi transfectionwas assessed byWestern
or, the NF-κB regulated reporter gene (3x(NF-κB)tk-Luc) and the internal control vector
i (100 nM). Twenty-four hours later cells were treated as above for 16 h where after cell
control RNAi in the presence of TPAwas given the nominal value of 100 and the results
±SD (n =3).
Fig. 6. TPA induces MKP-1 expression in HEK293 cells stably transfected with GRwt or
GRR488Q while dexamethasone induces MKP-1 expression only in HEK293 GRwt cells.
No evidence for a synergistic effect. HEK293 cells stably transfected with GRwt or
GRR488Q were treated with dexamethasone (100 nM), TPA (5 ng/ml) or a combination
thereof for 16 h and analyzed for MKP-1 expression by Western immunoblotting. Equal
protein loading in each lane was determined by re-probing the ﬁlters with a β-actin
antibody.
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effect of U0126 on TPA-stimulated Cox-2 and JunB expression was
mediated via other regulators of Cox-2 and JunB expression than
NF-κB.
3.4. The dual-speciﬁcity phosphatase MKP-1 is not involved in
GC-mediated repression of NF-κB activity in the presence of
activated ERK
Negative regulation of the ERK1/2 MAPK pathway can take place
through dephosphorylation of ERK1/2 by phosphatases, e.g. MAPK
phosphatase-1 (MKP-1). Previous reports have shown GC-mediated
inhibition of ERK1/2 phosphorylation concomitant with a GC-
stimulated up-regulation of MKP-1 expression [18,19,43] and it has
been suggested that MKP-1 may participate in the anti-inﬂammatory
actions of GCs [44]. However, the effect of MKP-1 on NF-κB is not
known. Unlike the GRwt, the GRR488Q mutant is not able to induce
MKP-1 gene expression following dexamethasone treatment (see
Fig. 6). This suggests the possibility that lack of MKP-1 induction
by GRR488Q was responsible for the inability of the mutant to
inactivate ERK1/2 and as a consequence was non-productive in GC-
mediated down-regulation of NF-κB activity (cf. Fig 3A and B). This
implies that inhibition of MKP-1 expression would result in a loss of
the ability of the GRwt to repress NF-κB activity. To evaluate the
importance of GC-stimulated MKP-1 expression in relation to GR-
mediated NF-κB repression, MKP-1 mRNA was targeted for degrada-
tion by RNA interference. For this purpose, HEK293 cells expressing
the GRwt were transfected with RNAi and the NF-κB reporter gene.
Cells transfected with MKP-1 RNAi displayed reduced MKP-1 mRNA
and protein expression as compared to transfection with control
RNAi following TPA stimulation alone or in the presence of
dexamethasone (Fig. 5A and B). Following reduction of MKP-1
expression by MKP-1 RNAi, the expression of the NF-κB reporter gene
revealed an increased response to TPA administration (Fig. 5C).
However, fold repression of NF-κB activity by dexamethasone in theFig. 7. No difference in phospho-ERK1/2 levels over time in GRwt and GRR488Q containing cell
with GRwt or GRR488Q were co-treated with dexamethasone (100 nM) and TPA (5 ng/ml)
immunoblotting. Lower panel, the membrane was stripped and reprobed with a phosphorypresence of TPA and MKP-1 RNAi was not affected in comparison to
when using control RNAi. The same results were seen on the
endogenous NF-κB regulated Cox-2 gene (Fig. 5D). These results
showed that GC-induced MKP-1 expression is not involved in GR-
mediated repression of NF-κB activity or Cox-2 expression in the
presence of activated ERK1/2. Furthermore, since TPA in itself was
much more efﬁcient in inducing MKP-1 expression in comparison to
dexamethasone in both GRwt and GRR488Q containing cells as assayed
by Western immunoblotting (Fig. 6), this further suggested that the
relatively weak induction of MKP-1 expression by dexamethasone in
GRwt containing cells did not contribute to the NF-κB repression by
GCs. Additionally, no synergistic activation of MKP-1 expression
following a combined treatment with TPA and dexamethasone was
observed (Fig. 6).
3.5. The differential ability to repress TPA-induced NF-κB activity by GRwt
vs. GRR488Q does not involve a difference in ERK1/2 dephosphorylation
To evaluate whether there was a difference in the ability of GRwt
and GRR488Q containing cells to differentially affect ERK1/2 activity
independent of MKP-1, we analyzed by Western immunoblotting, the
presence of activated ERK1/2 (phospho-ERK1/2) expression over time
in both GRwt and GRR488Q containing cells in the presence of both TPA
and dexamethasone. As can be seen in Fig. 7, activated ERK1/2
declined in both GRwt and GRR488Q containing cells. Importantly, no
difference in the presence of activated ERK1/2 over time (correspon-
ding to the time of TPA plus dexamethasone treatment in the
transfection experiments) between the cells was seen. In addition,
the change in activated ERK1/2 over time was not dependent on
whether dexamethasone was present or absent during TPA stimula-
tion (data not shown). Considering that ERK1/2 inhibition restored the
ability of GRR488Q to repress NF-κB activity (Fig. 3A and B), but no
difference in the ability of GRwt and GRR488Q to directly repress ERK1/2
activity was seen, suggested that the GRwt, in contrast to GRR488Q,
acted by inactivating or reversing ERK1/2-mediated effects allowing
NF-κB repression to occur.
4. Discussion
Cross-talk between the GR and NF-κB signaling is well recognized.
Also negative inﬂuence of GCs on MAPK pathway signaling has been
demonstrated (for reviews, see [4,17]). However, the importance of a
functional inactivation of ERK1/2 MAPK signaling by GCs in relation to
GR-mediated responses is not well established.
The GRR488Q, despite physically interacting with NF-κB, has an
impaired capacity to repress NF-κB activity following activation by the
phorbol ester TPA [36]. Interestingly, we here show that this is not the
case when NF-κB is activated by TNFα. This implies that mechanisms
additional to a physical GR interaction with NF-κB are important for
GC repression of NF-κB activity, mechanisms that are dependent on
concomitant signaling pathways activated in the cells. Using thes following co-treatment with TPA and dexamethasone. HEK293 cells stably transfected
and analyzed for phospho-ERK1/2 activity (upper panel) from 0 to 16 h by Western
lation state-independent ERK1/2 antibody.
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that efﬁcient GC repression of NF-κB requires inhibition of ERK1/2
signaling under conditions when this MAPK signaling pathway is
activated.
The importance of ERK1/2 MAPK signaling pathway inactivation
for GR repression of NF-κB activity in the HEK293 cells was directly
demonstrated using speciﬁc ERK1/2 inhibitors (dominant-negative
MEK-1 and U0126) that restored or enhanced the ability of GRR488Q to
repress NF-κB activity. This was also the case for endogenous NF-κB
regulated genes as demonstrated for Cox-2 and JunB. Furthermore,
GRR488Q maintains its capacity to repress AP-1 activity following TPA
stimulation [36]. These results together with the ability of the GRR488Q
to repress NF-κB following activation by TNFα, demonstrated that the
inability to repress NF-κB following activation by TPAwas not intrinsic
to the GRR488Q mutant but dependent on concomitant signaling
pathways activated in the cells. Why inhibition of ERK1/2 activity
restored or enhanced GRR488Q's ability to repress NF-κB activity and
endogenous NF-κB-regulated genes in the HEK293 is unclear, but is
unlikely to be related to an impaired GR function due to ERK1/2
mediated GR phosphorylation as previously suggested in other cells
[40,42]. This conclusion is based on that addition of U0126 did not
enhance the ability of GRR488Q to activate from a GRE in the presence
of activated ERK (Fig. 3C). Secondly, GRR488Q is still functional in
repression of AP-1 activity in HEK293 cells following stimulation by
TPA [36] and thirdly, the GR mutation does not involve a ERK1/2
phosphorylation site. Furthermore, ERK does not seem to inﬂuence
NF-κB activity following TPA or TNFα stimulation, since expression of
the dominant negativeMEK-1 plasmid or addition of the ERK inhibitor
U0126 had only minor or no effect on NF-κB activity (Fig. 3A and B and
data not shown). Instead, the ability of ERK1/2 to inﬂuence GR activity
may rather relate to the phosphorylation of other proteins e.g.
coactivators preventing GR to inhibit their activities. Indeed, Rogatsky
et al. have suggested that ERK inﬂuences GRwt transcriptional activity
indirectly, likely through a co-factor, in contrast to c-Jun N-terminal
kinase (JNK), which seems to mainly act via receptor phosphorylation
of Ser-246 [41]. In the absence of activated ERK1/2, as seen following
TNFα stimulation of HEK293 cells, the necessity of inactivation of
ERK1/2 effects is not required, allowing also GRR488Q to repress NF-κB
activity (Fig. 1). Why TNFα does not activate ERK1/2 MAPK signaling
in HEK293 cells is unclear.
Several studies have demonstrated an induction of MKP-1 in a
number of cell lines following GC administration [18,19,27–33].
However, the importance of MKP-1 induction by GCs for depho-
sphorylation of ERK and for GC-regulated responses is contradictory
[35,44–46]. Furthermore, an effect speciﬁcally on NF-κB activity by
GC-stimulated MKP-1 expression has not been established. Although
both Abraham et al. and Maier et al. in experiments using macro-
phages or mast cells with ablated MKP-1 expression presented con-
tradictory results with regard to the role of MKP-1 for GC repression
of target genes and anti-inﬂammatory effects in vivo, they both
showed that ablated MKP-1 expression impaired GC-mediated
repression of JNK and p38 MAPKs but had no effect on ERK
activation and its response to GCs [34,35]. While Maier et al. [35]
reported no impairment of the ability of GCs to repress proin-
ﬂammatory cytokines or chemokines in bone marrow derived mast
cells with ablated MKP-1 expression, Abraham et. al. [34] showed
impaired GC repression of a subset of NF-κB regulated inﬂammatory
mediators in bone marrow derived macrophages from MKP-1 knock-
out mice. This differential response of NF-κB regulated genes implies
that MKP-1 effects on NF-κB are not responsible for the differential
response to GCs. In line with this suggestion, we in the present
report were unable to demonstrate involvement of MKP-1 in the
regulation of ERK activity and GC repression of NF-κB activity in the
HEK293 cells. First, TPA treatment alone of HEK293 cells stably
expressing GRR488Q efﬁciently induced MKP-1 expression and this
induction was much more pronounced than the MKP-1 inductionseen following dexamethasone treatment of HEK293 GRwt cells
(Fig. 6). Thus, the contribution of MKP-1 expression by GCs in the
presence of TPA is minor. Secondly, although down-regulation of
MKP-1 expression using RNAi enhanced NF-κB activity and expres-
sion of the Cox-2 gene following TPA stimulation of HEK293 GRwt
cells, no effect on the fold repression by GCs was demonstrated
(Fig. 5). These results support our conclusion that GC-stimulated
expression of MKP-1 is not involved in the regulation of ERK and
NF-κB activity in the HEK293 cells and that the inability of GRR488Q to
repress ERK and NF-κB activity does not relate to the inability of
GRR488Q, in contrast to GRwt, to induce MKP-1 expression in response
to GCs. Importantly, no difference in levels of activated ERK1/2 was
seen overtime between GRwt and GRR488Q containing cells following
co-treatment of TPA and dexamethasone (Fig. 7). Also considering
that inhibition of activated ERK1/2 by a dominant negative MEK-1
mutant or the MEK inhibitor UO126 (Fig. 3A and B) restored the
ability of GRR488Q to repress NF-κB activity, suggests that GRwt
instead has the capacity, in contrast to GRR488Q, to alter ERK1/2-
mediated effects required for NF-κB repression to occur. In addition,
since ERK inhibition did not affect TPA-stimulated NF-κB activity
(Fig. 3A and B), it is unlikely that the enhancing effect of MKP-1 RNAi
on TPA-stimulated NF-κB activity and Cox-2 expression is mediated
via enhanced ERK activity. Rather, this may be mediated through
effects on other MKP-1 targets as p38 and JNK MAPKs. This is in line
with a preferred preference of MKP-1 for p38 and JNK over ERK ([47],
see also above). However, cell speciﬁc differences may exist because
blocking MKP-1 expression by RNAi in breast epithelial cell lines
hampers GC-mediated ERK dephosphorylation and cell survival
following paclitaxel induced cytotoxicity [26]. Similarly, regulation
of ERK by MKP-1 controls osteoblast proliferation in response to GCs
[45]. As an alternative, GCs may also block ERK activation indepen-
dent of MKP-1 expression as it has previously been shown that ERK2
activation can be repressed by dexamethasone already at the level of
Raf-1 [16].
Our results using GRR488Q showed that it was unable to repress
NF-κB activity following stimulation by the phorbol ester TPA, but did
so following activation by TNFα. This seemed to relate to the
differential activation of ERK1/2 in the HEK293 cells. This result
stresses that the nature of the inducer of NF-κB activity will have
profound effects on the mechanism by which the GR represses NF-κB.
This is in line with previous results from the laboratory of Glass and
co-workers, who showed that the GR only represses NF-κB depen-
dent target genes following activation by the Toll receptors TLR4 and
TLR9 but not following NF-κB activation by TLR3 [14, 15]. In this case,
the different signal transduction pathways used to activate NF-κB
resulted in differential co-activator utilization by NF-κB, which
constituted the basis for the differential GC response of NF-κB target
genes [14,15].
In summary, our experiments demonstrate that GR-mediated
inhibition of ERK signaling is involved in GC repression of NF-κB
activity in HEK293 cells when this signaling pathway is activated by
TPA. However, this does not involve GC inhibition of ERK itself and
instead seem to be dependent on GRwt inhibition of ERK1/2-mediated
effects, a capacity lacked by the GRR488Q mutant. Our results also
provided evidence for that GR-mediated repression of activated NF-κB
requires separate functions of the GR, functions that are dependent on
the signaling pathway employed to activate NF-κB. Finally, our results
underscore the complexity and diversity in the mechanisms involved
in GC repression of NF-κB activity.Acknowledgements
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